Express Scripts' Use Projections For Viekira Pak Unchanged By Label Update
This article was originally published in The Pink Sheet Daily
PBM already had programs in place to ensure AbbVie’s hepatitis C treatment was not provided to patients with severe liver disease, exec says.
You may also be interested in...
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.